CurrentCapital BluecrossPolicy MP 4.033

DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME

Policy governs coverage determination for eyelid thermal pulsation therapy, intense pulsed light (IPL) with meibomian gland expression, and near-infrared dual imaging meibography for management or diagnosis of dry eye syndrome (meibomian gland dysfunction) for Capital Blue Cross products (with product variations noted).

Policy Summary

PayerCapital Bluecross

PolicyDIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME

Policy CodePolicy MP 4.033

Change TypeConsensus reviewsinvestigational determination (03/25/2022)

Effective DateFeb 1, 2026

Next Review Date

Key ActionIdentification of a code in the coding section does not denote coverage; payment is subject to member's benefit program, eligibility, and medical necessity determinations.

SourceLink

POLICY UPDATE CHANGES

03/25/2022 - Changed eyelid thermal pulsation therapy or IPL to Not Medically Necessary (investigational); updated background, references, FEP.

05/26/2023 - Consensus review; no changes to policy statement; updated background/rationale/references.

06/20/2024 - Consensus review; no changes to policy statement; updated background/references; coding reviewed, no changes.

06/16/2025 - Consensus review; no change to policy statement; cross references, background and references updated; references added.

3Procedures deemed investigational (listed codes)

2011-2023FDA clearances summarized (device clearance years shown)

Low/Very LowCertainty of evidence per Cochrane / reviews

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary & Policy Statement

Policy MP 4.033 (effective 02/01/2026; last review 06/16/2025) governs coverage for eyelid thermal pulsation therapy, intense pulsed light (IPL) with meibomian gland expression, and near-infrared dual imaging meibography for management or diagnosis of dry eye syndrome (meibomian gland dysfunction). The policy determination is that these procedures are investigational / not covered (investigational; not medically necessary), because current evidence — including RCTs and systematic reviews — is of low to very low certainty and is insufficient to conclude a net health benefit.

Medically Necessary / Investigational Determinations

Policy statements:

Eyelid thermal pulsation therapy, or intense pulsed light with subsequent meibomian gland expression to treat dry eye are considered investigational as a management of Dry Eye Syndrome.
Near-infrared dual imaging of the Meibomian glands is considered investigational.
There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

Relevant Codes

Investigational / therefore not covered procedure codes (listed by policy)CPTNot Covered

0207T	Eyelid thermal pulsation / investigational per policy (listed)
0330T	Procedure code listed as investigational in coding section
0507T	Procedure code listed as investigational in coding section
0563T	Procedure code added 01/01/2020 and listed as investigational

Identification of a code in the coding section does not denote coverage; payment is subject to the member's benefit program, eligibility, and medical necessity determinations.

Policy applies only to certain programs/products administered by Capital Blue Cross; providers must verify product-specific benefits (for example, FEP PPO refers to the FEP Medical Policy Manual).

Provider Guidance & Billing Rules

Billing Rule

Claims subject to member benefit and medical necessity

Identification of a code in the coding section does not denote coverage; payment is subject to the member's benefit program, eligibility, and medical necessity determinations.

Documentation Required

Product variation and benefit checking

Policy applies only to certain programs/products; providers must verify product-specific benefits (e.g., FEP PPO referred to FEP Medical Policy Manual).

Note: FEP PPO – refer to FEP Medical Policy Manual

Background and Evidence Summary

Thermal pulsation devices apply localized heat and pulsatile pressure to the eyelids to express meibomian glands (examples: LipiFlow, iLux, TearCare), and some systems are FDA-cleared for treatment of MGD. Intense pulsed light (IPL) delivers wavelengths (about 550–1200 nm) to the eyelids and is often followed by manual gland expression. Near-infrared dual imaging (meibography) uses transillumination/infrared techniques to image meibomian gland structure.

Although randomized trials, systematic reviews (including a 2024 Cochrane review of LipiFlow) and observational studies exist, the overall certainty of the evidence is described as low to very low, and the evidence is insufficient to determine an improvement in net health outcome.

Evidence summaries

Definitions & scope

Policy Revision Timeline

03/25/2022material_change

03/25/2022 - Changed eyelid thermal pulsation therapy or intense pulsed light (IPL) to Not Medically Necessary (investigational); updated background, references, FEP.

05/26/2023consensus_review

05/26/2023 - Consensus review; no changes to policy statement; updated background, rationale, and references.

06/20/2024consensus_review

06/20/2024 - Consensus review; no changes to policy statement; updated background and references; coding reviewed with no changes.